KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TherapeuticsMD (TXMD) EPS (Weighted Average and Diluted) (2021 - 2025)

TherapeuticsMD (TXMD) has disclosed EPS (Weighted Average and Diluted) for 5 consecutive years, with $0.01 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EPS (Weighted Average and Diluted) rose 120.0% year-over-year to $0.01, compared with a TTM value of $0.02 through Sep 2025, up 104.26%, and an annual FY2024 reading of -$0.19, up 80.81% over the prior year.
  • EPS (Weighted Average and Diluted) was $0.01 for Q3 2025 at TherapeuticsMD, down from $0.05 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $17.3 in Q4 2022 and bottomed at -$12.39 in Q3 2022.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.84, with a median of -$0.13 recorded in 2023.
  • Peak annual rise in EPS (Weighted Average and Diluted) hit 447.39% in 2022, while the deepest fall reached 120.46% in 2022.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$4.98 in 2021, then soared by 447.39% to $17.3 in 2022, then plummeted by 101.5% to -$0.26 in 2023, then surged by 107.69% to $0.02 in 2024, then tumbled by 50.0% to $0.01 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for TXMD at $0.01 in Q3 2025, $0.05 in Q2 2025, and -$0.06 in Q1 2025.